The significant guidance reduction, particularly the swing to negative organic operational growth, signals a worsening demand environment in the core U.S. companion animal business. Traders should expect a negative reaction and watch for further competitive pressure on key franchises like dermatology and parasiticides, as well as potential for additional cost-cutting measures.
Drugs in focus
ZTS drug pipeline →Convenia
▼ Bearish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already on market since 2008
- Next catalyst
- None dated
What to watchConvenia is a mature, approved product facing generic erosion, a known headwind already priced into ZTS's ~50% decline from its 52-week high. The next meaningful catalyst for ZTS is its quarterly earnings (next likely in late October/November 2026), where Convenia generic impact will be visible in the companion animal segment. Investors should watch for further margin compression and market share loss to Dechra's Solovecin.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $77.05entry
- T+1 · 3mo ago −6.09%α −6.70% · $72.36
- T+5 · 3mo ago −1.67%α −2.89% · $75.76
- T+20 · 3mo ago −0.99%α −1.58% · $76.29
- T+60 · 18d ago +3.47%α +5.14% · $79.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zoetis reported Q2 2026 adjusted EPS of $1.87, a 1% beat vs. $1.85 consensus, but revenue of $2.468B slightly missed the $2.51B estimate. The company slashed its full-year 2026 guidance, now expecting revenue of $9.12B-$9.32B (organic operational decline of 3%-1%) and adjusted EPS of $6.15-$6.25, down sharply from prior guidance of $6.85-$7.00. The U.S. companion animal business continued to deteriorate, with sales falling 11% due to pet owner price sensitivity and heightened competition, offsetting strength in livestock and international segments. This is a clear bearish signal as the core U.S. franchise is under structural pressure, leading to a significant guidance reduction that will likely drive the stock lower.
Key Financial Metrics
Key Facts
- Q2 2026 revenue flat at $2.468B vs $2.474B YoY; organic operational revenue declined 1%
- Adjusted EPS of $1.87 beat consensus of $1.85 by 1%
- U.S. segment revenue fell 7% to $1.266B; companion animal sales dropped 11%
- Full-year 2026 revenue guidance slashed to $9.12B-$9.32B from $9.68B-$9.96B (organic operational growth of -3% to -1%)
- Full-year 2026 adjusted EPS guidance cut to $6.15-$6.25 from $6.85-$7.00
- Adjusted net income guidance for organic operational growth revised to -9% to -5% from +2% to +6%
- Restructuring charges of $77M in Q2, primarily for employee termination costs under a cost and productivity program
Financial Impact
Full-year revenue guidance cut by ~$560M-$640M at midpoint; adjusted EPS guidance cut by ~$0.70 at midpoint
Risk Factors
- Continued deterioration in U.S. companion animal demand due to pet owner price sensitivity
- Intensifying competition in key categories (dermatology, parasiticides) and generic erosion of Convenia/Cerenia
- Execution risk on cost restructuring program; potential for further guidance cuts if trends worsen
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001555280-26-000038 |
| Document: zts-20260806.htm | 0001555280-26-000038 |
| Document: 0001555280-26-000038-index-headers.html | 0001555280-26-000038 |
| Document: 0001555280-26-000038-index.html | 0001555280-26-000038 |
| Document: 0001555280-26-000038.txt | 0001555280-26-000038 |
| 8-K Data (Synthetic) | 0001555280-26-000038 |
Track record
10 reports on ZTS
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +38.10% at T+60 after the Feb 27, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $82.11 to $79.40 Now $84.39 −2.78% ▲ +3.30% +3.61% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $79.52 to $79.96 Now $84.39 +6.13% ▲ +0.55% +0.22% vs SPY
- Oct 13, 20264w ago 8-K Neutral 2/10 Entry $74.30 to $75.29 Now $84.39 +13.58% ▲ +1.33% +2.41% vs SPY
- Oct 8, 20265w ago 8-K Neutral 2/10 Entry $74.81 to $75.65 Now $84.39 +12.81% ▲ +1.12% +1.18% vs SPY
- Aug 6, 202614w ago 8-K Bearish 7/10 Viewing Entry $77.05 to $72.36 Now $84.39 −9.53% ▲ +6.09% +6.70% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $79.98 to $81.17 Now $84.39 +5.52% ▲ +1.49% +1.04% vs SPY
- May 13, 202626w ago Insider Cluster Neutral 2/10 Entry $75.24 to $73.62 Now $84.39 +12.16% ▼ −2.15% −0.93% vs SPY
- May 7, 202627w ago 8-K Bearish 7/10 Entry $87.24 to $82.31 Now $84.39 +3.27% ▲ +5.65% +6.48% vs SPY
- Apr 8, 202631w ago DEFA14A Neutral 2/10 Entry $119.65 to $119.47 Now $84.39 −29.47% ▼ −0.15% −0.72% vs SPY
- Feb 27, 202637w ago Court Ruling Bearish 6/10 Entry $127.51 to $124.52 Now $84.39 +33.82% ▲ +2.35% +1.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers